These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

852 related articles for article (PubMed ID: 11084061)

  • 1. An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy.
    Han SH; Ofman J; Holt C; King K; Kunder G; Chen P; Dawson S; Goldstein L; Yersiz H; Farmer DG; Ghobrial RM; Busuttil RW; Martin P
    Liver Transpl; 2000 Nov; 6(6):741-8. PubMed ID: 11084061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lamivudine after hepatitis B immune globulin is effective in preventing hepatitis B recurrence after liver transplantation.
    Dodson SF; de Vera ME; Bonham CA; Geller DA; Rakela J; Fung JJ
    Liver Transpl; 2000 Jul; 6(4):434-9. PubMed ID: 10915164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin.
    Markowitz JS; Martin P; Conrad AJ; Markmann JF; Seu P; Yersiz H; Goss JA; Schmidt P; Pakrasi A; Artinian L; Murray NG; Imagawa DK; Holt C; Goldstein LI; Stribling R; Busuttil RW
    Hepatology; 1998 Aug; 28(2):585-9. PubMed ID: 9696028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-dose hepatitis B immune globulin and higher-dose lamivudine combination to prevent hepatitis B virus recurrence after liver transplantation.
    Karasu Z; Ozacar T; Akyildiz M; Demirbas T; Arikan C; Kobat A; Akarca U; Ersoz G; Gunsar F; Batur Y; Kilic M; Tokat Y
    Antivir Ther; 2004 Dec; 9(6):921-7. PubMed ID: 15651751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term lamivudine monotherapy prevents development of hepatitis B virus infection in hepatitis B surface-antigen negative liver transplant recipients from hepatitis B core-antibody-positive donors.
    Prakoso E; Strasser SI; Koorey DJ; Verran D; McCaughan GW
    Clin Transplant; 2006; 20(3):369-73. PubMed ID: 16824156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination therapy in liver transplant recipients with hepatitis B virus without hepatitis B immune globulin.
    Neff GW; Kemmer N; Kaiser TE; Zacharias VC; Alonzo M; Thomas M; Buell J
    Dig Dis Sci; 2007 Oct; 52(10):2497-500. PubMed ID: 17404847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conversion from intravenous to intramuscular hepatitis B immune globulin in combination with lamivudine is safe and cost-effective in patients receiving long-term prophylaxis to prevent hepatitis B recurrence after liver transplantation.
    Han SH; Martin P; Edelstein M; Hu R; Kunder G; Holt C; Saab S; Durazo F; Goldstein L; Farmer D; Ghobrial RM; Busuttil RW
    Liver Transpl; 2003 Feb; 9(2):182-7. PubMed ID: 12548512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of lamivudine and adefovir without hepatitis B immune globulin is safe and effective prophylaxis against hepatitis B virus recurrence in hepatitis B surface antigen-positive liver transplant candidates.
    Gane EJ; Patterson S; Strasser SI; McCaughan GW; Angus PW
    Liver Transpl; 2013 Mar; 19(3):268-74. PubMed ID: 23447403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis B virus quasispecies evolution after liver transplantation in patients under long-term lamivudine prophylaxis with or without hepatitis B immune globulin.
    Buti M; Tabernero D; Mas A; Homs M; Prieto M; Rodríguez-Frías F; Casafont F; Casillas R; González A; Miras M; Herrero JI; Castells L; Esteban R
    Transpl Infect Dis; 2015 Apr; 17(2):208-20. PubMed ID: 25641570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B.
    Angus PW; McCaughan GW; Gane EJ; Crawford DH; Harley H
    Liver Transpl; 2000 Jul; 6(4):429-33. PubMed ID: 10915163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intramuscular hepatitis B immune globulin combined with lamivudine for prophylaxis against hepatitis B recurrence after liver transplantation.
    Yao FY; Osorio RW; Roberts JP; Poordad FF; Briceno MN; Garcia-Kennedy R; Gish RR
    Liver Transpl Surg; 1999 Nov; 5(6):491-6. PubMed ID: 10545536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized study comparing lamivudine monotherapy after a short course of hepatitis B immune globulin (HBIg) and lamivudine with long-term lamivudine plus HBIg in the prevention of hepatitis B virus recurrence after liver transplantation.
    Buti M; Mas A; Prieto M; Casafont F; González A; Miras M; Herrero JI; Jardí R; Cruz de Castro E; García-Rey C
    J Hepatol; 2003 Jun; 38(6):811-7. PubMed ID: 12763375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis B: progress in the last 15 years.
    Villamil FG
    Liver Transpl; 2002 Oct; 8(10 Suppl 1):S59-66. PubMed ID: 12362301
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of hepatitis B recurrence after liver transplantation using lamivudine and hepatitis B immune globulin.
    Ołdakowska-Jedynak U; Paczek L; Foroncewicz B; Mucha K; Nyckowski P; Zieniewicz K; Ziarkiewicz-Wróblewska B; Ziółkowski J; Pilecki T; Patkowski W; Górnicka B; Paczkowska A; Krawczyk M
    Ann Transplant; 2007; 12(3):28-32. PubMed ID: 18290567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evolving experience of hepatitis B virus prophylaxis in liver transplantation.
    Honaker MR; Shokouh-Amiri MH; Vera SR; Alloway RR; Grewal HP; Hardinger KL; Kizilisik AT; Bagous T; Trofe J; Stratta RJ; Egidi MF; Gaber AO
    Transpl Infect Dis; 2002 Sep; 4(3):137-43. PubMed ID: 12421458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New era of liver transplantation for hepatitis B: a 17-year single-center experience.
    Anselmo DM; Ghobrial RM; Jung LC; Weaver M; Cao C; Saab S; Kunder G; Chen PW; Farmer DG; Yersiz H; Baquerizo A; Geevarghese S; Han SH; Goldstein L; Holt CD; Gornbein JA; Busuttil RW
    Ann Surg; 2002 May; 235(5):611-9; discussion 619-20. PubMed ID: 11981206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation.
    Gane EJ; Angus PW; Strasser S; Crawford DH; Ring J; Jeffrey GP; McCaughan GW;
    Gastroenterology; 2007 Mar; 132(3):931-7. PubMed ID: 17383422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prophylactic use of low-dose, on-demand, intramuscular hepatitis B immunoglobulin and lamivudine after liver transplantation.
    Karademir S; Astarcioğlu H; Akarsu M; Ozkardesler S; Ozzeybek D; Sayiner A; Akan M; Tankurt E; Astarcioğlu I
    Transplant Proc; 2006 Mar; 38(2):579-83. PubMed ID: 16549180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatocellular carcinoma is associated with an increased risk of hepatitis B virus recurrence after liver transplantation.
    Faria LC; Gigou M; Roque-Afonso AM; Sebagh M; Roche B; Fallot G; Ferrari TC; Guettier C; Dussaix E; Castaing D; Brechot C; Samuel D
    Gastroenterology; 2008 Jun; 134(7):1890-9; quiz 2155. PubMed ID: 18424269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-dose intramuscular hepatitis B immune globulin and lamivudine for long-term prophylaxis of hepatitis B recurrence after liver transplantation.
    Ferretti G; Merli M; Ginanni Corradini S; Callejon V; Tanzilli P; Masini A; Ferretti S; Iappelli M; Rossi M; Rivanera D; Lilli D; Mancini C; Attili A; Berloco P
    Transplant Proc; 2004 Apr; 36(3):535-8. PubMed ID: 15110584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.